Exagen Inc (XGN) News

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 SCHEDULE 14AProxy Statement Pursuant to Section 14(a) of the Securities...

Current Report Filing (8-k)

0001274737FALSE00012747372023-05-152023-05-15UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...

Exagen Inc. Reports First Quarter 2023 Results

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of...

Current Report Filing (8-k)

0001274737FALSE00012747372023-04-282023-04-28UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...

Exagen Announces Campaign for Lupus Awareness Month

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

Annual Report to Security Holders (ars)

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 SCHEDULE 14AProxy Statement Pursuant to Section 14(a) of the Securities...

Proxy Statement (definitive) (def 14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 SCHEDULE 14AProxy Statement Pursuant to Section 14(a) of the Securities...

Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

Current Report Filing (8-k)

0001274737FALSE00012747372023-01-232023-01-23UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...

Annual Report (10-k)

2022FYFALSE0001274737P3Yhttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpenseP3Yhttp://fasb.org/us...

Current Report Filing (8-k)

0001274737FALSE00012747372023-03-202023-03-20UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023

SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...